Tweet

Biotech2k

2 Oct, 10 tweets, 2 min read

Profiling $ERAS:

This is a new IPO, but I jumped on it because of its management. This management was from the old Ignyta which was very successful for me in the past. I go into Ignyta early and held it until the day it was bought out. I know this is a winning management team.

1/ They remind me very much like $RVMD with a big focus on the MAPK pathway. They have no data yet, but they did dose their first patient. I would expect some early data in the Spring of next year.

2/ Their first targets are all about MAPK and using combinations of target to lock down this pathway in cancer. Many drugs will suppress the pathway, but it rebounds over time.

3/ They have their 2 lead drugs for SHP2 and ERK combined in combination for MAPK pathway related cancers. This could play a role in EFGR, RAS and RAF mutated cancers. We already know that SHP2 could be toxic based on data from other SPH2 programs by $RMVD and TNO-155.

4/ That leaves me a bit cautious with these first programs. They also have a SOS1 and EFGR inhibitor in discovery to work in combinations with SHP2 and ERK.

5/ They have no data yet in these programs so we will have to wait and see. I do know that SPH2 + MEK for $RVMD did not work out. Maybe SHP2 + ERK would, but that is yet to be determined.

6/ The rest of their pipeline is in discovery around RAS and KRAS. They are highly focused on kinase inhibitors, but they are also in discovery with protein degraders for some of the same targets.

7/ I have stated in the past that success in target protein degraders could replace kinases if they have same efficacy with less toxicity. The data for these drugs is way to early to even compare.

8/ I think the value of the company is expensive. $RVMD trades at $2 billion market cap with such big potential, but $ERAS trades at more than $2.5 billion with the same potential, but further behind in development.

9/ Maybe I can justify $500 million as reasonable for a management team I know is very good. This is another very promising company with a big potential of $3 to $5 billion that has no data yet. It will all come down to the data.

• • •

Missing some Tweet in this thread? You can try to force a refresh

This Thread may be Removed Anytime!

Twitter may remove this content at anytime! Save it as PDF for later use!

More from @Biotech2k1

Biotech2k

@Biotech2k1

2 Oct

Profiling $RPTX:

My last pathway company to profile for today. They are unique as they are focused on the DNA damage repair pathways. This is a new frontier of discovery. There are not a lot of companies in this space yet.

1/ They are my first and only pure Synthetic Lethality play. Their first drug is around the ATM/ATR pathway that regulates double stranded breaks. This concept looks for pathways that cancer depends on to drive growth. It targets them to kill the cancer cells.

2/ The ATM/ATR pathway has been attempted before. It has concerns with toxicity. There is a level of concern and caution about trying new things in this same area that failed before.

Read 6 tweets

Biotech2k

@Biotech2k1

2 Oct

Profiling $SDGR:

It took me a long time to warm up to $SDGR. For a long time, I just dismissed it as a tech company. I could care less about a tech company. Then I found out they were developing their own pipeline.

1/ Then again, I dismissed them as a tech company pretending to be a biotech. What would a tech company know about developing drugs? I listened to a few of their presentations from their science guru. That is when I thought they had potential.

2/ They have a lot of partnerships for companies using their software developing drugs. I am not going to cover any of those as they all have different terms and levels of profit sharing. They do offer potential should they work out.

Read 13 tweets

Biotech2k

@Biotech2k1

2 Oct

Profiling $RLAY:

I got into this company about 6 months ago. They are an early stage company with no data yet. They have a big risk/reward profile with using AI to attempt to take on some of the most toxic targets in pathways.

1/ I spoke before about how the SPH2 and PI3K kinases are at the top of the MAPK and mTOR pathways. Being at the top of the pathway gives them strong suppression effects, but a lot of toxicity. $RLAY is taking on these targets using its AI platform to develop inhibitors.

2/ Their fist program is around SHP2 which they already partnered out. This helps mitigate any failure if the technology doesn't help improve this target more then other companies. We have no data yet on this program. This has been turned over to the partner so data is waiting.

Read 11 tweets

Biotech2k

@Biotech2k1

2 Oct

Profiling $RVMD:

I got into this company early this year. I love the pathways they are targeting, but they have little data or success yet to show they have great science yet.

1/ Their management is still new to me as they haven't had much data yet. Their first program was for SHP2 which had lack luster data. At least they were wise enough to partner that away for some cash. They are highly focused on the internal cell growth pathways.

2/ These are the MAPK and mTOR pathways. These are some of the hottest pathways in all oncology. The problem is the closer to the receptor you go for the pathways, the broader the suppression and the higher the toxicity.

Read 8 tweets

Biotech2k

@Biotech2k1

2 Oct

Profiling $MRTX:

I got interested in $MRTX about 3 years ago while I was an Array Bio investor. They licensed some of the KRAS technology from Array. That got me interested.

1/ $MRTX just replaced their CEO. Chuck moved up to Chairman and they hired David Meek to groom into the new CEO role. He has a history with commercial experience. That is good for taking the company to the next level with approval and sales.

2/ Their original drug is Sitravatinib which hits multiple kinases. This is designed to alter the tumor microenvironment to shift things back toward cellular killing. It had some decent data for patients who developed resistance to PD-1 inhibitors.

Read 16 tweets

Biotech2k

@Biotech2k1

2 Oct

Profiling $TPTX:

I have been in this company just over a year now. I am pretty sure the management is strong, but it hasn't had the chance to navigate the entire process yet. They still need to show they can get a drug approved and execute on selling it.

1/ This company is working on the growth receptors pathways. They are a 2nd generation of kinase company. They are developing much smaller inhibitors that can get in there and still inhibit the kinase even with mutation. That is their big tech development.

2/ Their drugs are designed to get around and overcome resistance. Will they develop resistances of their own? My money would be on yes as cancer always mutates to find a way around most drugs.

Read 15 tweets

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!